Thank you for submitting your manuscript for consideration by The EMBO Journal. I apologise that it has taken longer than expected to have your manuscript reviewed but I have now received the final report from the two referees who evaluated your study and I enclose their comments below. As you will see they currently provide mixed recommendations, while referee #2 is positive regarding the study, referee #1 request a more direct link between cordanin-1/ASF1 and CDAI to make the study suitable for EMBO J, and I suggest that you focus on this aspect and a couple of more minor issues including point 5 in a revised version of the manuscript. If you are able to address these concerns we would like to invite you to submit a revised version of the manuscript.
I should remind you that it is EMBO Journal policy to allow a single round of revision only and that, therefore, acceptance or rejection of the manuscript will depend on the completeness of your responses included in the next, final version of the manuscript. When you submit a revised version to the EMBO Journal, please make sure you upload a letter of response to the referees' comments. Please note that when preparing your letter of response to the referees' comments that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process initiative, please visit our website: http://www.nature.com/emboj/about/process.html Thank you for the opportunity to consider your work for publication. I look forward to your revision.
Yours sincerely, Editor
The EMBO Journal _____ REFEREE REPORTS:
Referee #1 (Remarks to the Author):
The authors identify codanin-1 as a new binding partner of the histone binding protein, ASF1. They present evidence that codanin-1 regulates DNA synthesis, through its interaction with ASF1. In addition, they show two naturally occurring mutants of codanin-1 thought to be responsible for the disease, congenital dyserythropoietic anaemia type I (CDAI), are impaired in their ability to bind to ASF1 and regulate DNA synthesis. The demonstration that codanin-1 is an ASF1 binding protein that regulates its function is important for the field, and all the more so if disease mutations disrupt this function. But, there are significant weaknesses that preclude publication in EMBOJ at this time. Most importantly, the authors show that the disease mutations of codanin-1 disrupt this specific in vitro function of the protein, but there is no evidence presented that this function suppresses cellular phenotypes associated with the disease. Ideally, I would like to see the authors take CDAI cell lines and rescue defects in those cell lines by specific restoration of the codanin-1/ASF1 function. Without more direct evidence that this cordanin-1/ASF1 function is disrupted in CDAI the current work is better suited for a more specialized journal.
Other points. 1. Figure 1b shows a subset of the data in Figure 1d , and so the former can be removed.
2. The authors conclude that codanin-1 is in complex with ASF1 specifically in the cytosol. The authors should perform a subcellular fractionation and IP-western, with markers to control for proper cell fractionation.
3. Figure 1c . This Figure shows that codanin-1 binds to ASF1 in a way that should preclude binding to HIRA and CAF1. The authors should confirm that HIRA and CAF1a are not co-precipitated with codanin-1 from cell lysates (e.g. in Figure 1D ).
4. Figure 3c . The authors show that knock down of codanin-1 increases the proportion of EdU positive cells and their staining intensity. This is difficult to reconcile with Figure S3B that shows no change in cell cycle distribution by PI staining after cordanin-1 knock down. The authors need to reconcile this. Analyzing progression through G1 and S phase in synchronized cells might help. Or, is the EdU incorporation in knock down cells a result of DNA damage and repair coupled DNA synthesis that does not affect cell cycle distribution?
5. The authors show that two codanin-1 mutants R714W and R1042W do not bind to ASF1b. However, these mutations are within a domain of the protein that, in Figure 2a , the authors show is neither necessary nor sufficient for binding to ASF1. These results need to be better reconciled. Do these point mutants have a non-specific disruptive effect on protein folding? Or does the C-terminus somehow contribute to binding in the context of full-length protein?
Page 5. The B domain was first identified by Kirov et al in Drosophila. This work should be cited.
Referee #2 (Remarks to the Author):
This study reveal a function for codanin as a negative regulator of Asf1, which is a central player in histone turnover. Although the interaction between codanin and Asf1 has been reported before, this study rigorously establish this interesting interaction and provided much needed function. The quality of data is good and generally supported the conclusions. Although I am very much intrigued by the role of codanin in the nucleus, it is beyond the scope of this study. The current paper establish a clear role of codanin in the cytoplasm as one of the gatekeepers for proper histone H3/H4 supplies, the experiments covers both protein depletion and over expression, and the interpretations are fairly straightforward. Overall, this is an interesting story which provide new molecular insights into histone turnover. The connection to disease is nice but not essential for the main message of the paper. I recommend publication. We are pleased that the reviewer finds this work important for the field and overall we agree that analysis of cells from CDAI patients would be important to dissect comprehensively the basis of the disease. However, given that there (to the best of our knowledge) are no CDAI cell lines available recapitulating the erythroblast specific cellular phenotypes of the patients, this would require access to patient material in order to culture and manipulate primary erythroblasts. We feel that such an analysis is beyond the scope of this work as also supported by the comments of reviewer 2. Furthermore, we do not think that our work shows that the disease mutations of Codanin-1 disrupt an in vitro function of the protein. We identify a function of Codanin-1 in regulation of Asf1 function and DNA replication in human cells. Our analysis of inducible cell lines shows that CDAI mutants are impaired in their ability to inhibit DNA replication and in forming complex with Asf1. This illustrates a general defect in regulation of Asf1 in these mutant proteins. The erythroblast specific phenotypes such as spongy heterochromatin and high incidence of chromatin-bridges are not recapitulated in other cell types (U-2-OS and HeLa cells by over-expression or RNAi in this study, EBV transformed CDAI lymphoblasts (Renella et al., 2011. Blood)) and thus cannot be addressed. However, the failure in controlling Asf1 function and DNA replication that we identify could very well be relevant to the S-phase defect observed in erythroblast from CDAI patients. In order to strengthen this point and in a reasonable amount of time to provide additional evidence that the 'Codanin-1/Asf1 interaction is disrupted in CDAI', we directly tested the ability of the R714W CDAI mutant to substitute for endogenous Codanin-1 in regulation of Asf1. To this end, we carriedout complementation experiments in our inducible cell lines and assayed accumulation of Asf1 on chromatin (New Figure 6A , 6B and Figure S6 ). Codanin-1 depletion significantly increased the level of chromatin-bound Asf1. Expression of wild type Codanin-1 rescued this phenotype ( Figure 6A and Figure S6) and further reduced the level of Asf1 on chromatin, probably due to the high expression level. In contrast, the CDAI mutant R714W failed to rescue, and Asf1 levels on chromatin remained high ( Figure 6B and Figure S6 ). This further demonstrates that Codanin-1 mutants found in CDAI patients are defective in regulation of Asf1, supporting that this defect may contribute to some of the phenotypes associated with CDAI disease.
Other points.
1. Figure 1b shows a subset of the data in Figure 1d , and so the former can be removed.
We have removed lower panel of Figure 1B .
The authors conclude that codanin-1 is in complex with ASF1 specifically in the cytosol. The authors should perform a subcellular fractionation and IP-western, with markers to control for proper cell fractionation.
We have used a well-established protocol to make nuclear and cytosolic extracts, previously used to analyse Asf1 complexes (Jasencakova et al., 2010. Mol Cell; Groth et al., 2007. Science) . A control for the quality of the extracts is now included in Figure S1A (new), with Importin-4 and CAF-1 p150 serving as cytosolic and nuclear markers, respectively. This shows that the vast majority of Codanin-1 is cytosolic, while Asf1 (a and b) is present in both cytosolic and nuclear fractions. The analysis of Codanin-1 in Asf1 complexes isolated from nuclear and cytosolic extracts is shown in Figure S1B . Both western blotting and mass spectrometry show that Codanin-1 is most abundant in cytosolic Asf1 complexes ( Figure 1A and Figure S1B ).
3. Figure 1c . This Figure shows that Figure 1D ).
To address this question we immunoprecipitated Codanin-1 from whole cell lysates, considering that HIRA and CAF-1 p150 are nuclear proteins. Whereas Asf1 readily co-purified with FLAG-HAtagged Codanin-1, neither HIRA nor the CAF-1 p60 and p150 subunits could be detected in Codanin-1 complexes (new Figure S1D ). This supports our finding that Codanin-1 binds to the same pocket in Asf1 as HIRA and CAF-1 p60, precluding a common complex.
Figure 3c. The authors show that knock down of codanin-1 increases the proportion of EdU positive cells and their staining intensity. This is difficult to reconcile with Figure S3B that shows no change in cell cycle distribution by PI staining after cordanin-1 knock down. The authors need to reconcile this. Analyzing progression through G1 and S phase in synchronized cells might help. Or, is the EdU incorporation in knock down cells a result of DNA damage and repair coupled DNA synthesis that does not affect cell cycle distribution?
Cells depleted for Codanin-1 do not show DNA damage, as measured by γH2AX in western blotting (New Figure S4B) or RPA coated ssDNA in immunofluorescence analysis (data not shown). This excludes that the higher rate of EdU incorporation is due to repair-coupled DNA synthesis. The lack of DNA damage probably also explains why we do not see major changes in cell cycle distribution, since checkpoints are not turned on. A change in replication speed is not necessarily reflected by the steady state cell cycle distribution as other cell cycle phases may also be affected directly or indirectly. We tried to analyse G1 and S phase progression by addition of nocodazole to trap the cell in G2/M, as suggested by the reviewer. However, this did not reveal a clear difference for Codanin-1 depleted cells, perhaps because FACS analysis is not sufficiently sensitive to detect an increase in S phase rate (data not shown). However, one prediction is that cells may proliferate more rapidly overall. Thus, we measured proliferation of Codanin-1 depleted cells and indeed cell counts were consistently higher as compared with control cultures (New Figure S3C) . The moderate increase in cell numbers after 56hrs of Codanin-1 depletion correlates with increased EdU incorporation and is consistent with a proliferation advantage due to elevated replication speed in the absence of DNA damage and cell cycle arrest. We hope these new pieces of evidence satisfy the reviewers concern. This is an important point and we have now analysed in vitro whether CDAI disease mutations (R714W and R1042W) affect the interaction between Codanin-1 and Asf1 ( Figure S5A ). Our data show that these CDAI mutants do not disrupt binding to GST-Asf1 (a and b) in vitro (New Figure  S5A) . However, the situation is clearly more complex in vivo, where the same CDAI mutants consistently show reduced ability to form complex with Asf1 (a and b) ( Figure 5B ). To strengthen this point we have quantified Asf1 levels in complexes containing wild type and mutant Codanin-1 in three independent experiments (see bar-diagram Figure 5B) . Moreover, complementation analysis shows that the R714W mutant cannot substitute for endogenous Codanin-1 in regulation of Asf1 function (See discussion above and New Figure 6 ). Thus, while CDAI mutations do not directly abrogate Asf1 binding, they clearly compromise the ability of Codanin-1 to act as a negatively regulator of Asf1 and control DNA replication. We envision that CDAI mutations might target a region that indirectly aids efficient complex formation with Asf1 i.e. by abrogating binding to other yet to be discovered partner(s). We discuss this point in our revised manuscript. We are very pleased that reviewer #2 finds our work interesting and of high quality, and that he/she recommends publication in EMBO Journal without further experiments.
The authors show that two codanin-
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